Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Cited by (1,030)

Items 801–900 of 1,030

1. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
   Elias Daud, Offir Ertracht, Nadav Bandel, Gassan Moady, Mona Shehadeh, Tali Reuveni, Shaul Atar · 2021 · Cardiovascular Diabetology
2. Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S111–S134
   American Diabetes Association · 2020 · Diabetes Care
3. Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy
   Anurag Choksey, Kerstin N. Timm · 2021 · International Journal of Molecular Sciences
4. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?
   Aditi Ujjawal, Brittany Schreiber, Ashish Verma · 2022 · Therapeutic Advances in Endocrinology and Metabolism
5. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure
   Luís Eduardo Paim Rohde, André Zimerman, Muthiah Vaduganathan, Brian Lee Claggett, Milton Packer, Akshay Suvas Desai, Michael R. Zile, Jean Lucien Rouleau, Karl B Swedberg, Martin P. Lefkowitz et al. · 2022 · JAMA Cardiology
6. A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes
   R. Bouchi, Tatsuya Kondo, Yasuharu Ohta, A. Goto, D. Tanaka, Hiroaki Satoh, D. Yabe, R. Nishimura, N. Harada, H. Kamiya et al. · 2022 · Journal of Diabetes Investigation
7. Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
   Scheen, André J., Bonnet, Fabrice · 2023 · Diabetes & Metabolism
8. Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
   Jong‐Chan Youn, Darae Kim, Jae Yeong Cho, Dong‐Hyuk Cho, Sang Min Park, Mi‐Hyang Jung, Junho Hyun, Hyun‐Jai Cho, Seong‐Mi Park, Jin‐Oh Choi et al. · 2023 · International Journal of Heart Failure
9. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
   Safia Chatur, Muthiah Vaduganathan, Brian Lee Claggett, Finnian R. Mc Causland, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod et al. · 2023 · Journal of the American College of Cardiology
10. Myocardial Sodium–Glucose Cotransporter 2 Expression and Cardiac Remodelling in Patients with Severe Aortic Stenosis: The BIO-AS Study
    Lucia Scisciola, Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Leen Delrue, Fatemeh Taktaz, Rosaria Anna Fontanella, Ivan Degrieck, Ada Pesapane, Filip P A Casselman et al. · 2024 · European Journal of Heart Failure
11. Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies
    Nikolaos Mylonas, Panagiota Nikolaou, Paschalis Karakasis, Panagiotis Stachteas, Nikolaos Fragakis, Ioanna Andreadou · 2024 · International Journal of Molecular Sciences
12. Trials and tribulations of cell therapy for heart failure: an update on ongoing trials
    J. Zhang, Steven M. Pogwizd, Keiichi Fukuda, Wolfram H. Zimmermann, Cheng-Ming Fan, Joshua M. Hare, Roberto Bolli, Philippe Menasché · 2024 · Nature Reviews Cardiology
13. Clinical Management and Therapeutic Optimization of Patients with Heart Failure with Reduced Ejection Fraction and Low Blood Pressure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC
    Hadi N. Skouri, Nicolas Girerd, Luca Monzo, Mark Colquhoun Petrie, Michael Böhm, Marianna Adamo, Wilfried Müllens, Gianluigi Savarese, Mehmet Birhan Yılmaz, Offer Amir et al. · 2025 · European Journal of Heart Failure
14. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
    Tobias Täger, Dan Atar, Stefan Agewall, Hugo Albert Katus, Morten Grundtvig, John G.F. Cleland, Andrew L. Clark, Hanna Fröhlich, Lutz Frankenstein · 2020 · Heart Failure Reviews
15. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model
    Kevin M. Pantalone, Anita D. Misra‐Hebert, Todd M. Hobbs, Sheldon Xiaodong Kong, Xinge Ji, Rahul Ganguly, Alex Milinovich, Wayne Weng, Janine M. Bauman, Paul Petraro et al. · 2020 · Diabetes Care
16. The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
    Nicholas Keisuke Brownell, Boback Ziaeian, Gregg C. Fonarow · 2021 · Cardiac failure review
17. Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY
    Jinnie J. Rhee, Meg Jardine, Glenn Matthew Chertow, Kenneth W. Mahaffey · 2020 · Diabetes Obesity and Metabolism
18. Genetic Evidence for Repurposing of GLP1R (Glucagon‐Like Peptide‐1 Receptor) Agonists to Prevent Heart Failure
    Iyas Daghlas, Ville Karhunen, Devleena Ray, Verena Zuber, Stephen Burgess, Philip S. Tsao, Julie Ann Lynch, Kyung Min Lee, Benjamin F. Voight, Kyong‐Mi Chang et al. · 2021 · Journal of the American Heart Association
19. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
    Kieran F. Docherty, Modele O. Ogunniyi, Inder S. Anand, Akshay Suvas Desai, Mirta Díez, Jonathan G. Howlett, José Carlos Nicolau, Eileen O’Meara, Subodh Verma, Silvio E. Inzucchi et al. · 2021 · JACC Heart Failure
20. Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
    Jing Xu, Taro Hirai, Daisuke Koya, Munehiro Kitada · 2021 · Journal of Clinical Medicine
21. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
    Husam M. Salah, Subodh Verma, Carlos G. Santos‐Gallego, Ankeet S. Bhatt, Muthiah Vaduganathan, Muhammad Shahzeb Khan, Renato D. Lópes, Subhi Jamal Alaref, Darren K. McGuire, Marat Fudim · 2022 · Journal of Cardiovascular Translational Research
22. Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies
    Sanne de Wit, Claire Glen, Rudolf A. de Boer, Ninian N. Lang · 2022 · Cardiovascular Research
23. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
    Roko Škrabić, Marko Kumrić, Josip Vrdoljak, Doris Rušić, Ivna Skrabic, Marino Vilović, Dinko Martinović, Vid Duplancic, Tina Tičinović Kurir, Joško Božić · 2022 · Biomedicines
24. C–H Glycosylation of Native Carboxylic Acids: Discovery of Antidiabetic SGLT-2 Inhibitors
    Sanshan Wang, Kaiqi Chen, Fusheng Guo, Wenneng Zhu, Chendi Liu, Haoran Dong, Jin‐Quan Yu, Xiaoguang Lei · 2023 · ACS Central Science
25. Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research
    Jason Z. Li, Y. Robert Li · 2023 · Cardiology
26. Targeted delivery of MerTK protein via cell membrane engineered nanoparticle enhances efferocytosis and attenuates atherosclerosis in diabetic ApoE−/− Mice
    Shuo Qiu, Jiahan Liu, Jianmei Chen, Yangni Li, Te Bu, Zhelong Li, Liang Zhang, Wenqi Sun, Tian Zhou, Wei Hu et al. · 2024 · Journal of Nanobiotechnology
27. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
    Jung‐Im Shin, Yunwen Xu, Alex R. Chang, Juan Jesús Carrero, Carina M. Flaherty, Amrita Mukhopadhyay, Lesley A. Inker, Saul Blecker, Leora Idit Horwitz, Morgan Erika Grams · 2024 · Journal of the American College of Cardiology
28. A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?
    RUSSELL L. ESTERLINE, Jan Oscarsson, Jeffrey Murray Burns · 2020 · International review of neurobiology
29. Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors
    Mei Qiu, Liang‐Liang Ding, Ze‐Lin Zhan, Shu-Yan Liu · 2021 · Endocrine
30. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
    Muhammad Shahzeb Khan, Gary Michael Felker, Ileana L. Piña, Alexander Camacho, Devavrat Bapat, Nasrien E. Ibrahim, Alan S. Maisel, MARGARET FORNEY PRESCOTT, Jonathan H. Ward, Scott David Solomon et al. · 2020 · JACC Heart Failure
31. The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?
    Abhipree Sharma, Michael Mah, Rebecca Helen Ritchie, Miles J. De Blasio · 2021 · Pharmacology & Therapeutics
32. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
    David Z.I. Cherney, Jacob Allen Udell, Daniel J. Drucker · 2021 · Med
33. SGLT2 Inhibitors and Their Antiarrhythmic Properties
    Ewald Kolesnik, Daniel Scherr, Ursula Rohrer, Martin Benedikt, Martin Manninger, Harald Sourij, Dirk von Lewinski · 2022 · International Journal of Molecular Sciences
34. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura, Baroni, Marco Giorgio · 2020 · Advances in Experimental Medicine and Biology
35. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials
    Tsai, Wan-Chuan, Hsu, Shih-Ping, Chiu, Yen-Ling, Yang, Ju-Yeh, Pai, Mei-Fen, Ko, Mei-Ju, Tu, Yu-Kang, Hung, Kuan-Yu, Chien, Kuo-Liong, Peng, Yu-Sen et al. · 2022 · BMJ Open
36. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease
    Akira Mima · 2021 · Advances in Therapy
37. Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts
    Yuxin Chu, Cheng Zhang, Min Xie · 2021 · Frontiers in Aging
38. Drug Layering in Heart Failure
    Giuseppe M.C. Rosano, Larry A. Allen, Amr Abdin, JoAnn M. Lindenfeld, Eileen O’Meara, Carolyn S.P. Lam, Patrizio Lancellotti, Gianluigi Savarese, Stephen S. Gottlieb, John R. Teerlink et al. · 2021 · JACC Heart Failure
39. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
    Kristina V. Charaya, Dmitry Shchekochikhin, Denis A. Andreev, Irina Dyachuk, Svetlana Tarasenko, Maria G. Poltavskaya, Меситская Динара Фератовна, Alexandra A. Bogdanova, Natalia Ananicheva, А. A. Kuzub · 2022 · Open Heart
40. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
    Nam Hoon Kim, Nan Hee Kim · 2022 · Diabetes & Metabolism Journal
41. Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
    Ivona Mustapić, Darija Baković, Zora Sušilović Grabovac, Josip A. Borovac · 2022 · Journal of Clinical Medicine
42. The anti-inflammatory and immunological properties of SGLT-2 inhibitors
    Giulia Bendotti, Laura Bacchelli Montefusco, Ida Pastore, Elisa Lazzaroni, Maria Elena Lunati, Paolo Fiorina · 2023 · Journal of Endocrinological Investigation
43. Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1
    Bin Li, Wen‐Wu Bai, Tao Guo, Zhenyu Tang, Xuejiao Jing, Tichao Shan, Sen Yin, Ying Li, Fu Wang, Mo‐Li Zhu et al. · 2024 · Nature Communications
44. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data
    Patrick Bidulka, David Gibran Lugo-Palacios, Orlagh Carroll, Stephen O’Neill, Amanda Adler, Anirban Basu, Richard J. Silverwood, Jonathan William Bartlett, Dorothea Nitsch, Paul Charlton et al. · 2024 · BMJ
45. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients
    Yasuaki Nakagawa, Koichiro Kuwahara · 2020 · Journal of Cardiology
46. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Ona Kinduryte, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev · 2020 · Advances in Therapy
47. Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence
    Jose S. Aguilar-Gallardo, Ashish Adrian Correa, Johanna Contreras · 2021 · European Heart Journal - Cardiovascular Pharmacotherapy
48. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)
    Justin A. Ezekowitz, Yinggan Zheng, Alain Cohen Solal, Vojtěch Melenovský, Jorge Escobedo, Javed Butler, Adrian F. Hernandez, Carolyn S.P. Lam, Christopher M. O’Connor, Burkert Mathias Pieske et al. · 2021 · Circulation
49. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States
    Veer Sangha, Kasia J. Lipska, Zhenqiu Lin, Silvio E. Inzucchi, Darren K. McGuire, Harlan M. Krumholz, Rohan Khera · 2021 · Circulation Cardiovascular Quality and Outcomes
50. Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
    Giugliano, Dario, Longo, Miriam, Scappaticcio, Lorenzo, Caruso, Paola, Esposito, Katherine · 2021 · Cardiovascular Diabetology
51. SGLT2 Inhibitors in Liver Patients
    Hsiang, John Chen, Wong, Vincent Wai-Sun · 2020 · Clinical Gastroenterology and Hepatology
52. Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy
    Lisa Dannenberg, Dorothee Zikeli, Marcel Benkhoff, Samantha Ahlbrecht, Malte Kelm, Bodo Levkau, Amin Polzin · 2020 · Pharmacology & Therapeutics
53. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care
    Samuel Seidu, Xavier Cos, Stephen Brunton, Stewart B. Harris, Stefan P. O. Jansson, Manel Mata‐Cases, A.M.J. Neijens, Pınar Topsever, Kamlesh K. Khunti · 2022 · Primary care diabetes
54. Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
    Xuan Li, Elizabeth R. Flynn, Jussara Marcia do Carmo, Zhen Wang, Alexandre A. da Silva, Alan J. Mouton, Ana Carolina Mieko Omoto, Michael E. Hall, John Edward Hall · 2022 · Frontiers in Cardiovascular Medicine
55. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
    Ameenathul M. Fawzy, José Miguel Rivera‐Caravaca, Paula Underhill, Laurent Fauchier, Gregory Y.H. Lip · 2022 · Diabetes Obesity and Metabolism
56. Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain
    Carlos Escobar, Beatriz Palacios, Luis F. Varela, Martín Gutiérrez, Mai Duong, Hungta Chen, Nahila Justo, Javier Cid-Ruzafa, Ignacio Hernández, Phillip R. Hunt et al. · 2022 · Journal of Clinical Medicine
57. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
    Marc Evans, Angharad R. Morgan, Sarah Davies, Hannah Beba, William David Strain · 2022 · Age and Ageing
58. Immunomodulation and immunopharmacology in heart failure
    George Markousis‐Mavrogenis, Lukas Baumhove, Ali A. Al‐Mubarak, Joseph Pierre Aboumsallem, Nils Bömer, Adriaan A. Voors, Peter van der Meer · 2023 · Nature Reviews Cardiology
59. Heart failure and diabetes: Understanding the bidirectional relationship
    Chukwuka Elendu, Dependable C. Amaechi, Tochi C. Elendu, Manizha Ashna, Jennifer Ross-Comptis, Sandra O. Ansong, Emmanuel O. Egbunu, Geraldine C. Okafor, Klein A. Jingwa, Akinbayo A. Akintunde et al. · 2023 · Medicine
60. Baroreflex Activation Therapy in Patients with Heart Failure and a Reduced Ejection Fraction: Long-Term Outcomes
    Michael R. Zile, JoAnn M. Lindenfeld, Fred A. Weaver, Faiez M. Zannad, Elizabeth G. Galle, Tyson B. Rogers, William T. Abraham · 2024 · European Journal of Heart Failure
61. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy
    Michinari Nakamura · 2024 · Journal of Pharmacy & Pharmaceutical Sciences
62. Finerenone in Patients With a Recent Worsening Heart Failure Event
    Akshay Suvas Desai, Muthiah Vaduganathan, Brian Lee Claggett, Ian J. Kulac, Pardeep S. Jhund, Jonathan W. Cunningham, Maria Borentain, James Lay‐Flurrie, Prabhakar Viswanathan, Katja Rohwedder et al. · 2024 · Journal of the American College of Cardiology
63. Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus
    Juan José Gorgojo Martínez, José Luis Górriz, Ana María Cebrián Cuenca, Almudena Castro Conde, María Velasco · 2024 · Journal of Clinical Medicine
64. Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry
    Viveca Ritsinger, Thomas Nyström, Nawsad Saleh, Bo Lagerqvist, Anna Norhammar · 2020 · European Journal of Preventive Cardiology
65. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists
    Cesare Berra, Roberto Manfrini, Damiano Regazzoli, Maria Grazia Radaelli, Olga Disoteo, Carmen Sommese, Paolo Fiorina, Giuseppe Ambrosio, Franco B. Folli · 2020 · Pharmacological Research
66. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
    Hsin‐Fu Lee, Shao‐Wei Chen, Jia‐Rou Liu, Pei‐Ru Li, Lung‐Sheng Wu, Shang‐Hung Chang, Yung‐Hsin Yeh, Chi-Tai Kuo, Yi‐Hsin Chan, Lai‐Chu See · 2020 · Cardiovascular Diabetology
67. Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications
    Marc Evans, Angharad R. Morgan, Dipesh Patel, Ketan Dhatariya, Sharlene Anuska Greenwood, Philip Newland‐Jones, Debbie Hicks, Zaheer R Yousef, Jim Moore, Bethany Kelly et al. · 2020 · Diabetes Therapy
68. Sodium‐glucose co‐transporter‐2 inhibitors and all‐cause mortality: A meta‐analysis of randomized controlled trials
    Giovanni Antonio Silverii, Matteo Monami, Edoardo Mannucci · 2020 · Diabetes Obesity and Metabolism
69. Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
    Jens Aberle, Markus Menzen, Sebastian Michael Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus Florian Scheerer, John Xu, Weifeng Tang, Andreas L. Birkenfeld · 2020 · Scientific Reports
70. SGLT2i Versus ARNI in Heart Failure with Reduced Ejection Fraction: A Systematic Review and Meta-Analysis
    Yuling Yan, Bin Liu, Jun Cheng Du, Jing Wang, Xiaodong Jing, Yajie Liu, Songbai Deng, Jianlin Du, Qiang She · 2021 · ESC Heart Failure
71. Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia
    Mohammed Ali Azam, Praloy Chakraborty, Daoyuan Si, Beibei Du, Stéphane Massé, Patrick F.H. Lai, Andrew C.T. Ha, Kumaraswamy Nanthakumar · 2021 · Life Sciences
72. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction
    Jawad H. Butt, Kieran F. Docherty, Mark Colquhoun Petrie, Morten Schou, Mikhail Kosiborod, Eileen O’Meara, Tzvetana Katova, Charlotta E. A. Ljungman, Mirta Díez, Modele O. Ogunniyi et al. · 2021 · JAMA Cardiology
73. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
    Yan Xie, Benjamin C. Bowe, Andrew K. Gibson, Janet B. McGill, Geetha S. Maddukuri, Ziyad Al‐Aly · 2021 · JAMA Internal Medicine
74. Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
    Yi-Wen Yu, Xue-Mei Zhao, Yun-Hong Wang, Qiong Zhou, Yan Huang, Mei Zhai, Jian Zhang · 2021 · Cardiovascular Diabetology
75. Heart failure in adults with congenital heart disease
    Margarita Brida, Daniel Lovrić, Massimo Griselli, Fernando Gil, Michael Α. Gatzoulis · 2022 · International Journal of Cardiology
76. Nutritional Considerations During Major Weight Loss Therapy: Focus on Optimal Protein and a Low-Carbohydrate Dietary Pattern
    Volek, Jeff S., Kackley, Madison L., Buga, Alex · 2024 · Current Nutrition Reports
77. Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes
    John E. Anderson · 2020 · Diabetes Spectrum
78. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
    David Thein, Mia Nielsen Christiansen, Ulrik Madvig Mogensen, Johan Skov Bundgaard, Rasmus Rørth, Christian Madelaire, Emil Loldrup Fosbøl, Morten Schou, Christian Tobias Torp-Pedersen, Gunnar Gislason et al. · 2020 · Cardiovascular Diabetology
79. Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study
    Mikhail Kosiborod, Otavio B Berwanger, Gary G. Koch, Felipe A. Martínez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Ali Javaheri, Phil Ambery, Samvel B. Gasparyan et al. · 2020 · Diabetes Obesity and Metabolism
80. Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
    Mariusz Dąbrowski · 2021 · International Journal of Molecular Sciences
81. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload
    Masaaki Nakao, Ippei Shimizu, Goro Katsuumi, Yohko Yoshida, Masayoshi Suda, Yuka Hayashi, Ryutaro Ikegami, Yung‐Ting Hsiao, Shujiro Okuda, Tomoyoshi Soga et al. · 2021 · Scientific Reports
82. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis
    Min Li, Tieci Yi, Fangfang Fan, Lin Qiu, Zhi Wang, Haoyu Weng, Wei Ma, Yan Zhang, Yong Huo · 2022 · Cardiovascular Diabetology
83. Sex and Gender Bias as a Mechanistic Determinant of Cardiovascular Disease Outcomes
    Isabel Kim, Thalia S. Field, Darryl Wan, Karin H. Humphries, Tara Sedlak · 2022 · Canadian Journal of Cardiology
84. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials
    Yuichiro Mori, Obidiugwu Kenrik Duru, Katherine R. Tuttle, Shingo Fukuma, Daisuke Taura, Norio Harada, Nobuya Inagaki, Kosuke Inoue · 2022 · The Journal of Clinical Endocrinology & Metabolism
85. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial
    Anna Veelen, Charlotte Andriessen, Yvo J.M. Op den Kamp, Edmundo Erazo‐Tapia, Marlies de Ligt, Julian Mevenkamp, Johanna A. Jörgensen, Esther Moonen‐Kornips, Gert Schaart, RUSSELL L. ESTERLINE et al. · 2022 · Metabolism
86. Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Francisco Leyva, Carsten Walter Israel, Jagmeet P. Singh · 2023 · Circulation
87. Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies
    Nilanjan Ghosh, Leena Chacko, Hiranmoy Bhattacharya, Jayalakshmi Vallamkondu, Sagnik Nag, Abhijit Dey, Tanushree Karmakar, P. Hemachandra Reddy, Ramesh J. L. Kandimalla, Saikat Dewanjee · 2023 · Biomedicines
88. Modulation of the nitric oxide/cGMP pathway in cardiac contraction and relaxation: Potential role in heart failure treatment
    Rocco Mollace, Federica Scarano, Irene Bava, Cristina Carresi, Jessica Maiuolo, Annamaria Tavernese, Micaela Gliozzi, Vincenzo Musolino, Saverio Muscoli, Ernesto Palma et al. · 2023 · Pharmacological Research
89. Heart Failure in Patients with Chronic Kidney Disease
    Andrew V. Xanthopoulos, Adamantia Papamichail, Αlexandros Briasoulis, Konstantinos Loritis, Angeliki Bourazana, Dimitrios E. Magouliotis, Pantelis A. Sarafidis, Ioannis Stefanidis, John S. Skoularigis, Filippos K. Triposkiadis · 2023 · Journal of Clinical Medicine
90. SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1
    Weijie Wang, Yilan Li, Yanxiu Zhang, Tao Ye, Kui Wang, Shuijie Li, Yao Zhang · 2023 · Cardiovascular Diabetology
91. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Journal of Cardiac Failure
92. Euglycemic Diabetic Ketoacidosis
    Michael C. Plewa, M G Bryant, Robin King-Thiele · 2021 · StatPearls
93. Effects of Dapagliflozin on Congestion Assessed by Remote Pulmonary Artery Pressure Monitoring
    Wilfried Müllens, Pieter Martens, Omid Forouzan, Jeroen Dauw, Jan Vercammen, Evert Luwel, Wendy Ceyssens, Veerle Kockaerts, Koen Ameloot, Matthias Dupont · 2020 · ESC Heart Failure
94. Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
    Alex Ali Sayour, Attila Oláh, Mihály Ruppert, Bálint András Barta, Eszter Maria Horvath, Kálmán Benke, Miklós Pólos, István L. Hartyánszky, Béla Péter Merkely, Tamás Radovits · 2020 · Cardiovascular Diabetology
95. Reverse Cardiac Remodeling and ARNI Therapy
    Andrew Abboud, James L. Januzzi · 2021 · Current Heart Failure Reports
96. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options
    Jean‐Sébastien Hulot, Jean‐Noël Trochu, Erwan Donal, Michel Galinier, Damien Logeart, Pascal de Groote, Yves Juillière · 2021 · Expert Opinion on Pharmacotherapy
97. Cardio-Oncology
    Anja Karlstaedt, Matthew Barrett, Ray Hu, Seth T. Gammon, Bonnie Ky · 2021 · JACC Basic to Translational Science
98. Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications
    John Arthur McClung, Lior Levy, Victor G Garcia, David E. Stec, Stephen J. Peterson, Nader G. Abraham · 2021 · Pharmacology & Therapeutics
99. Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society
    Samuel Lévy, Gerhard Steinbeck, Luca Santini, Michael Näbauer, Diego Penela, Bharat K. Kantharia, Sanjeev V. Saksena, Riccardo Cappato · 2022 · Journal of Interventional Cardiac Electrophysiology
100. Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced
     Faiez M. Zannad, João Pedro Ferreira, John Gregson, Bettina Johanna Kraus, Michaela Mattheus, Sibylle Jenny Hauske, Javed Butler, Gerasimos S Filippatos, Christoph Wanner, Stefan D. Anker et al. · 2022 · European Journal of Heart Failure